Physician profile

Marcus D Biggers

Sports Medicine (Orthopaedic Surgery) · Arlington, TN

NPI 1962636605

$1,664.86

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$266.44

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Gentleman Orthopedic Solutions $1,200.00 2022
Encore Medical, LP $251.83 2024 Djo Surgical
Depuy Synthes Sales INC. $76.05 2020
Exactech, INC. $43.91 2019
Pacira Therapeutics, INC. $40.87 2021
Novo Nordisk INC $21.22 2021
Anika Therapeutics, INC. $14.61 2023 Tactoset
Zyla Life Sciences, INC. $12.76 2020
Kinex Medical Company LLC $3.61 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Marcus D Biggers

$1,664.86

in general payments reported 2019-2025

Years
2019-2024
Top company
Gentleman Orthopedic Solutions

https://glasscript.com/doctor/316531/marcus-d-biggers

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.